Drug Approval | December 17, 2025
Lupin receives EIR from USFDA for Nagpur injectable facility
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
The inspection concluded with one minor observation in Form 483
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Subscribe To Our Newsletter & Stay Updated
